AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38995646 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 181
Study 38995684 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003 (live-attenuated tetravalent dengue vaccine)
Number of subjects: 0
Study 38995684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38995690 — intervention group
Group type: EXPERIMENTAL
Intervention: Imlifidase (IgG endopeptidase)
Number of subjects: 0
Study 38995690 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-6 receptor (tocilizumab) or anti-IL-6 (clazakizumab)
Number of subjects: 0
Study 38995690 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD38 and anti-B-cell maturation antigen×CD3
Number of subjects: 0
Study 38995690 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement inhibitors and novel agents aimed at inhibiting Fc neonatal receptor IgG recycling
Number of subjects: 0
Study 38996086 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Department Code Sepsis Protocol
Number of subjects: 0
Study 38996086 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38996196 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 600
Study 38996201 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Docetaxel, Oxaliplatin, and S-1 plus surgery and adjuvant S-1
Number of subjects: 0
Study 38996333 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Interactive Multimodal Intervention (CIMI)
Number of subjects: 245
Study 38996333 — intervention group
Group type: COMPARATOR
Intervention: Control group (self-guided intervention)
Number of subjects: 245
Study 38996463 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR22 at 1 million CAR T cells per kg
Number of subjects: 40
Study 38996463 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR22 at 3 million CAR T cells per kg
Number of subjects: 40
Study 38996463 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose of CAR22
Number of subjects: 40
Study 38996463 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CAR T-cell product manufacturing
Number of subjects: 40
Study 38996463 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient outcomes
Number of subjects: 40
Study 38996519 — intervention group
Group type: EXPERIMENTAL
Intervention: FU/FA + Pmab
Number of subjects: 387
Study 38996519 — intervention group
Group type: COMPARATOR
Intervention: FU/FA
Number of subjects: 387
Study 38996972 — intervention group
Group type: EXPERIMENTAL
Intervention: 1HP (daily rifapentine plus isoniazid for 28 days)
Number of subjects: 490
Study 38996972 — intervention group
Group type: COMPARATOR
Intervention: 3HP (weekly rifapentine plus isoniazid for 3 months)
Number of subjects: 490
Study 38997091 — intervention group
Group type: EXPERIMENTAL
Intervention: Home induction with a transcervical Foley catheter
Number of subjects: 45
Study 38997091 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (control group)
Number of subjects: 45
Study 38997229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir-based regimen (135 participants)
Number of subjects: 268
Study 38997229 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz-based regimen (133 participants)
Number of subjects: 268
Study 38997229 — intervention group
Group type: EXPERIMENTAL
Intervention: Clay-based Traditional Medicine (TM) use (34% of participants)
Number of subjects: 268
Study 38997229 — intervention group
Group type: EXPERIMENTAL
Intervention: Mumbwa (clay-based TM) coadministration
Number of subjects: 268
Study 38997279 — intervention group
Group type: COMPARATOR
Intervention: Gut microbiota-based machine learning (ML) algorithms for ALD diagnosis
Number of subjects: 263
Study 38997279 — intervention group
Group type: COMPARATOR
Intervention: Gut microbiota-based machine learning (ML) algorithms for MASLD diagnosis
Number of subjects: 263
Study 38997279 — intervention group
Group type: COMPARATOR
Intervention: Gut microbiota-based machine learning (ML) algorithms for ALD and MASLD external validation
Number of subjects: 263
Study 38997435 — intervention group
Group type: EXPERIMENTAL
Intervention: Total testosterone
Number of subjects: 907
Study 38997435 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 907
Study 38997435 — intervention group
Group type: EXPERIMENTAL
Intervention: SHBG
Number of subjects: 907
Study 38997439 — intervention group
Group type: EXPERIMENTAL
Intervention: SOPeD web-based foot-ankle therapeutic exercise program
Number of subjects: 62
Study 38997439 — intervention group
Group type: COMPARATOR
Intervention: Usual care for diabetic foot
Number of subjects: 62
Study 38997441 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Pilates Group (OPG)
Number of subjects: 0
Study 38997441 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 0
Study 38997607 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) therapy
Number of subjects: 12
Study 38997620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily for 12 months
Number of subjects: 60
Study 38997620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 38997647 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable surfaces (UNST)
Number of subjects: 62
Study 38997647 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable surfaces (ST)
Number of subjects: 62
Study 38997647 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isometric quadriceps strength (UNST)
Number of subjects: 62
Study 38997647 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isometric quadriceps strength (ST)
Number of subjects: 62
Study 38997647 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 38997668 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral blood pressure measurement
Number of subjects: 4517
Study 38997676 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (48 weeks duration)
Number of subjects: 347
Study 38997676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 38997684 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized visualized oral health education combined with conventional oral hygiene education
Number of subjects: 56
Study 38997684 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral hygiene education only
Number of subjects: 56
Study 38999331 — intervention group
Group type: EXPERIMENTAL
Intervention: Centhaquine
Number of subjects: 0
Study 39001374 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha DaRT treatment
Number of subjects: 71
Study 39001413 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective observational cohort study
Number of subjects: 102
Study 39001413 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and biological samples collection
Number of subjects: 102
Study 39001413 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PRO) data collection
Number of subjects: 102
Study 39001621 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-metronidazole-tetracycline and clarithromycin-amoxicillin-bismuth quadruple therapies
Number of subjects: 53636
Study 39001621 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant clarithromycin-amoxicillin-tinidazole/metronidazole
Number of subjects: 53636
Study 39001621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential clarithromycin-amoxicillin-tinidazole/metronidazole
Number of subjects: 53636
Study 39001621 — intervention group
Group type: COMPARATOR
Intervention: Dyspepsia with normal endoscopy
Number of subjects: 53636
Study 39001621 — intervention group
Group type: COMPARATOR
Intervention: Duodenal ulcer
Number of subjects: 53636
Study 39001621 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal ulcer and preneoplastic lesions
Number of subjects: 53636
Study 39001621 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment effectiveness by indication
Number of subjects: 53636
Study 39001736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging (MRI)
Number of subjects: 80
Study 39001864 — intervention group
Group type: EXPERIMENTAL
Intervention: Jewel patch wearable cardioverter-defibrillator (P-WCD) delivering a single shock of 150 J
Number of subjects: 18
Study 39001910 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 282
Study 39001910 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (AC)
Number of subjects: 282
Study 39001910 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) in patients ≤50 years
Number of subjects: 282
Study 39001910 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (AC) in patients ≤50 years
Number of subjects: 282
Study 39001910 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) in patients >50 years
Number of subjects: 282
Study 39001910 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (AC) in patients >50 years
Number of subjects: 282
Study 39001922 — intervention group
Group type: EXPERIMENTAL
Intervention: mXACT Total Prosthesis Offcenter
Number of subjects: 103
Study 39001922 — intervention group
Group type: EXPERIMENTAL
Intervention: mXACT Total Prosthesis Center, mXACT Total Prosthesis Offcenter, mXACT PRO Total Prosthesis
Number of subjects: 103
Study 39002005 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional economic incentives based on PrEP adherence grading system ($20 for high adherence, $10 for medium adherence, $0 for low adherence)
Number of subjects: 110
Study 39002005 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional economic incentives
Number of subjects: 110
Study 39002092 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab Q2W
Number of subjects: 178
Study 39002092 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab Q4W
Number of subjects: 178
Study 39002092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 39002122 — intervention group
Group type: EXPERIMENTAL
Intervention: TCK-276 25 mg/day
Number of subjects: 32
Study 39002122 — intervention group
Group type: EXPERIMENTAL
Intervention: TCK-276 75 mg/day
Number of subjects: 32
Study 39002122 — intervention group
Group type: EXPERIMENTAL
Intervention: TCK-276 175 mg/day
Number of subjects: 32
Study 39002122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 39002328 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program (4 group sessions and 6 follow-up phone calls)
Number of subjects: 197
Study 39002328 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 197
Study 39002346 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-NHL-HG29 questionnaire for high-grade NHL
Number of subjects: 3922
Study 39002346 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-NHL-LG20 questionnaire for low-grade NHL
Number of subjects: 3922
Study 39002346 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-HL27 questionnaire for Hodgkin lymphoma
Number of subjects: 3922
Study 39002346 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable regression analyses for DLBCL, follicular and HL
Number of subjects: 3922
Study 39002347 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 53
Study 39002347 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPTEM
Number of subjects: 53
Study 39002409 — intervention group
Group type: EXPERIMENTAL
Intervention: Pushing technique with saline
Number of subjects: 60
Study 39002551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (10 mg twice daily for ages 12-18, 5 mg twice daily for ages 6-12, 4 mg/m² for ages 2-6)
Number of subjects: 45
Study 39002551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 45
Study 39002624 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (caloric intake)
Number of subjects: 115
Study 39002624 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise habits
Number of subjects: 115
Study 39002624 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use (alcohol, tobacco, marijuana)
Number of subjects: 115
Study 39002625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy sourced medical abortion (mifepristone and misoprostol)
Number of subjects: 2000
Study 39002625 — intervention group
Group type: COMPARATOR
Intervention: Clinic sourced medical abortion (mifepristone and misoprostol)
Number of subjects: 2000
Study 39002625 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 2000
Study 39002641 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemvidutide treatment
Number of subjects: 94
Study 39002641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 39002945 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban with aspirin
Number of subjects: 0
Study 39002945 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban alone
Number of subjects: 0
Study 39002945 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study 39003135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative burden and increasing trends of body mass index (BMI) originating in childhood
Number of subjects: 0
Study 39003135 — intervention group
Group type: EXPERIMENTAL
Intervention: Early weight management
Number of subjects: 0
Study 39003182 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil administered concomitantly to radiotherapy
Number of subjects: 10
Study 39003185 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant durvalumab plus platinum-based chemotherapy (D+CT) followed by adjuvant durvalumab
Number of subjects: 140
Study 39003185 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation durvalumab after chemoradiotherapy
Number of subjects: 140
Study 39003185 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant D+CT followed by surgery or chemoradiotherapy
Number of subjects: 140
Study 39003225 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive lipomodeling reconstruction after mastectomy (Group 1)
Number of subjects: 91
Study 39003225 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipomodeling reconstruction in addition to a flap (Group 2)
Number of subjects: 91
Study 39003225 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive lipomodeling reconstruction after tumorectomy (Group 3)
Number of subjects: 91
Study 39003225 — intervention group
Group type: COMPARATOR
Intervention: Postoperative complications across all groups
Number of subjects: 91
Study 39003306 — intervention group
Group type: EXPERIMENTAL
Intervention: gBRCA1/2 mutations
Number of subjects: 471
Study 39003306 — intervention group
Group type: COMPARATOR
Intervention: Non-gBRCA1/2 mutation carriers
Number of subjects: 471
Study 39003306 — intervention group
Group type: COMPARATOR
Intervention: Other cancer risk gene mutations
Number of subjects: 471
Study 39003306 — intervention group
Group type: COMPARATOR
Intervention: Somatic mutations (e.g., TP53, CDH1, PTEN)
Number of subjects: 471
Study 39003347 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycoprotein (MYC)
Number of subjects: 24
Study 39003347 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 24
Study 39003423 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic diagnostic algorithm for systematic classification of interatrial communications
Number of subjects: 12385
Study 39003483 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hysteroscopy (2 times: early and late) in group A
Number of subjects: 66
Study 39003483 — intervention group
Group type: COMPARATOR
Intervention: Late hystroscopy (6 months post suction D&C) in group B
Number of subjects: 66
Study 39003483 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 66
Study 39003487 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-regional pro-atrial natriuretic peptide (MRproANP)
Number of subjects: 418
Study 39003487 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 418
Study 39003487 — intervention group
Group type: EXPERIMENTAL
Intervention: Midregional pro-adrenomedullin (MRproADM)
Number of subjects: 418
Study 39003753 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task Timed Up-and-Go test (cognitive) (DTUG)
Number of subjects: 0
Study 39003753 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-m walk backward test (3MBWT)
Number of subjects: 0
Study 39003935 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP
Number of subjects: 99
Study 39003935 — intervention group
Group type: EXPERIMENTAL
Intervention: PMRE
Number of subjects: 99
Study 39003935 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 99
Study 39003957 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie Restriction (CR)
Number of subjects: 44
Study 39003957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting (IF)
Number of subjects: 44
Study 39003957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD)
Number of subjects: 44
Study 39003957 — intervention group
Group type: COMPARATOR
Intervention: Ad Libitum Habitual Diet (AL)
Number of subjects: 44
Study 39004096 — intervention group
Group type: EXPERIMENTAL
Intervention: H3N2 M2SR vaccine plus Fluzone HD (n=94)
Number of subjects: 305
Study 39004096 — intervention group
Group type: EXPERIMENTAL
Intervention: H3N2 M2SR vaccine plus placebo (n=89)
Number of subjects: 305
Study 39004096 — intervention group
Group type: COMPARATOR
Intervention: Fluzone HD plus placebo (n=92)
Number of subjects: 305
Study 39004096 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone (n=30)
Number of subjects: 305
Study 39004211 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasinumab clinical trials (not specified dosage or duration)
Number of subjects: 21997
Study 39004211 — intervention group
Group type: COMPARATOR
Intervention: X-ray imaging
Number of subjects: 21997
Study 39004211 — intervention group
Group type: COMPARATOR
Intervention: MRI imaging
Number of subjects: 21997
Study 39004217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion for 48 hours to maintain HR at 60 to 90 beats/min
Number of subjects: 90
Study 39004217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 90
Study 39004223 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Glycemic Index Mediterranean-Style Eating Pattern (MED-HEP)
Number of subjects: 160
Study 39004223 — intervention group
Group type: COMPARATOR
Intervention: High-Glycemic Index Mediterranean-Style Eating Pattern (MED-HEP)
Number of subjects: 160
Study 39004283 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized nutritious food (SNF) and social and behavior change communication (SBCC) intervention
Number of subjects: 2928
Study 39004283 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2928
Study 39004298 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent online training (IND)
Number of subjects: 210
Study 39004298 — intervention group
Group type: COMPARATOR
Intervention: Maintenance of Certification-4 (MOC) activity
Number of subjects: 210
Study 39004432 — intervention group
Group type: EXPERIMENTAL
Intervention: ixekizumab (IXE) 80 mg every 4 weeks
Number of subjects: 81
Study 39004434 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-Denmark vaccine (0.05 mL intradermal dose)
Number of subjects: 1272
Study 39004434 — intervention group
Group type: COMPARATOR
Intervention: No BCG vaccination
Number of subjects: 1272
Study 39004647 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-A1811 at 4.8 mg/kg
Number of subjects: 63
Study 39004647 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-A1811 at 8.0 mg/kg
Number of subjects: 63
Study 39004647 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Number of subjects: 63
Study 39004647 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-A1811 at 6.4 mg/kg
Number of subjects: 63
Study 39004848 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical restraint
Number of subjects: 647
Study 39004848 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-psychotic medications
Number of subjects: 647
Study 39004848 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis
Number of subjects: 647
Study 39004848 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic drug abuse
Number of subjects: 647
Study 39005691 — intervention group
Group type: EXPERIMENTAL
Intervention: Debulking therapy (including rituximab-containing immunochemotherapy regimens and radiotherapy)
Number of subjects: 50
Study 39005691 — intervention group
Group type: EXPERIMENTAL
Intervention: Axi-cel treatment
Number of subjects: 50
Study 39005691 — intervention group
Group type: EXPERIMENTAL
Intervention: Debulking chemotherapy
Number of subjects: 50
Study 39006159 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-based follow-up
Number of subjects: 152
Study 39006159 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 152
Study 39006315 — intervention group
Group type: EXPERIMENTAL
Intervention: RBL (REBYOTA®) administration after non-CDI antibiotic use
Number of subjects: 43
Study 39006315 — intervention group
Group type: COMPARATOR
Intervention: High-risk antibiotics
Number of subjects: 43
Study 39006430 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% eyedrops twice daily for four weeks
Number of subjects: 2500
Study 39006430 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for four weeks
Number of subjects: 2500
Study 39006430 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% eyedrops
Number of subjects: 2500
Study 39006430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study 39006439 — intervention group
Group type: EXPERIMENTAL
Intervention: Epcoritamab-containing regimens
Number of subjects: 0
Study 39007062 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab treatment
Number of subjects: 339
Study 39007062 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 339
Study 39007065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) at a dose of 30 mg/m² combined with cyclophosphamide and vincristine (VPC)
Number of subjects: 34
Study 39007065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) at a dose of 30 mg/m²
Number of subjects: 34